Hypoxia and metastasis in breast cancer

Breast Disease

Volumn 26, Issue 1, 2006, Pages 55-64

  Chaudarya, Naz ^a   Hill, Richard P ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Department of Medical Biophysics ^*  (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast carcinoma; Gene expression; Hypoxia; Metastasis; Transient changes; Tumor microenvironment

Indexed keywords

CARBONATE DEHYDRATASE IX; CHEMOKINE RECEPTOR CXCR4; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2; OSTEOPONTIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CAUSE OF DEATH; CELL GROWTH; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HYPOXIA; IMMUNOLOCALIZATION; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR; SYSTEMIC THERAPY; TISSUE OXYGENATION; TUMOR CELL; UPREGULATION;

EID: 34247528557     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2007-26105     Document Type: Article

References (124)

1. M.Z. Dewan, S. Ahmed, Y. Iwasaki, K. Ohba, M. Toi and N. Yamamoto, Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer, Biomed Pharmacother 60 (2006), 273-276.
2. S. Paget, The distribution of sedondary growths in cancer of the breast. 1889, Cancer Metastasis Rev 8 (1989), 98-101.
3. I.J. Fidler, The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited, Nat Rev Cancer 3 (2003), 453-458.
4. J.M. Brown and W.R. Wilson, Exploiting tum our hypoxia in cancer treatment, Nat Rev Cancer 4 (2004), 437-447.
5. R.G. Boyle and S. Travers, Hypoxia: Targeting the tumour, Anticancer Agents Med Chem 6 (2006), 281-286.
6. K.S. Kimbro and J.W. Simons, Hypoxia-inducible factor-1 in human breast and prostate cancer, Endocr Relat Cancer 13 (2006), 739-749.
7. A. Fyles, M. Milosevic, M. Pintilie, A. Syed, W. Levin, L. Manchul and R.P. Hill, Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer, Radiother Oncol 80 (2066), 132-137.
8. P. Vaupel, The role of hypoxia-induced factors in tumor progression, Oncologist 9(Suppl 5) (2004), 10-17.
9. P. Subarsky and R.P. Hill, The hypoxic tumour microenvironment and metastatic progression, Clin, Exp Metastasis 20 (2003), 237-250.
10. K. Maseide, T. Kalliomaki and R.P. Hill, Mircroenvironmental Effects on Tumour Progression and Metastasis, in: Integration/Interaction of Oncologic Growth, (Vol. 15), G.G. Meadows, ed., 2005, p. 1.
11. G.L. Semenza, HIF-1: Mediator of physiological and patho-physiologal responses to hypoxia, J Appl Physiol 88 (2000), 1474-1480.
12. N.C. Denko, L.A. Fontana, K.M. Hudson, P.D. Sutphin, S. Raychaudhuri, R. Altman and A.J. Giaccia, Investigating hypoxic tumor physiology through gene expression patterns, Oncogene 22 (2003), 5907-5914.
13. G.L. Semenza, Regulation of Physiological Responses to Continuous and Intermittent Hypoxia by hypoxia-Inducible Factor 1, Exp Physiol (2006).
14. A. Lal, H. Peters, B. St Croix, Z. A. Haroon, M.W. Dewhirst, R.L. Strausberg, J.H. Kaanders, A.J. van der Kogel and G.J. Riggins, Transcriptional response to hypoxia in human tumors, J Natl Cancer Inst 93 (2001), 1337-1343.
15. A.F. Chambers, A.C. Groom and I.C. MacDonald, Dissemination and growth of cancer cells in metastatic sites, Nat Rev Cancer 2 (2002), 563-572.
16. M. Schindl, S.F. Schoppmann, H. Samonigg, H. Hausmaninger, W. Kwasny, M Gnant, R. Jakesz E. Kubista, P. Birner and G. Oberhuber, Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer, Clin Cancer Res 8 (2002), 1831-1837.
17. A.L. Harris, Hypoxia - a key regulatory factor in tumour growth, Nat Rev Cancer 2 (2002), 38-47.
18. T.I. Goonewardene, H.M. Sowter and A.L. Harris, Hypoxia-induced pathways in breast cancer, Microsc Res Tech 59 (2002), 41-48.
19. Q.T. Le, N.C. Denko and A.J. Giaccia, Hypoxic gene expression and metastasis, Cancer Metastasis Rev 23 (2004), 293-310.
20. A Verma, Oxygen-sensing in tumors, Curr Opin Clin Nutr Metab Care 9 (2006), 366-378.
21. G. Pitson, A. Fyles, M. Milosevic, J. Wylie, M. Pintilie and R. Hill, Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer, Int J Radiat Oncol Biol Phys 51 (2001), 699-703.
22. J. Zhou, T. Schmid, S. Schnitzer and B Brune, Tumor hypoxia and cancer progression, Cancer Lett 237 (2006), 10-21.
23. M. Kinoshita, D.L. Johnson, C.H. Shatney, Y.L. Lee and H. Mochizuki, Cancer cells surviving hypoxia obtain hypoxia resistance and maintain anti-apoptotic potential under reoxygenation, Int J Cancer 91 (2001), 322-326.
24. S.M. Evans and C.J. Koch, Prognostic significance of tumor oxygenation in humans, Cancer Lett 195 (2003), 1-16.
25. R.A. Gatenby, H.B. Kessler, J.S. Rosenblum, L.R. Coia, P.J. Moldofsky, W.H. Hartz and G.J. Broder, Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy, Int J Radiat Onool Biol Phys 14 (1988), 831-838.
26. M. Hockel and P. Vaupel, Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects, J Natl Cancer Inst 93 (2001), 266-276.
27. D. Hedley, M. Pintilie, J. Woo, A. Morrison, D. Birle, A. Fyles, M. Milosevic and R. Hill, Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas, Clin Cancer Res 9 (2003), 5666-5674.
28. P. Vaupel, A. Mayer, S. Briest and M. Hockel, Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion, Adv Exp Med Biol 566 (2005), 333-342.
29. F. Kallinowski, R. Zander, M. Hoeckel and P. Vaupel, Tumor tissue oxygenation as evaluated by computerized-pO2-histography, Int J Radiat Oncol Biol Phys 19 (1990), 953-961.
30. P. Vaupel, A. Mayer, S. Briest and M. Hockel, Oxygenation gain factor: A novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers, Cancer Res 63 (2003), 7634-7637.
31. P. Vaupel, K. Schlenger, C. Knoope and M. Hockel, Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancer by computerized O2 tention measurements, Cancer Res 51 (1991), 3316-3322.
32. P. Hohenberger, C. Felgner, W. Haensch and P.M. Schlag, Tumor oxygenation correlates with molecular growth determinants in breast cancer Breast Cancer Res Treat 48 (1998), 97-106.
33. G.L. Semenza, Hypoxia, clonal selection, and the role of HIF-1 in tumor progression, Crit Rev Biochem Mol Biol 35 (2000), 71-103.
34. I.P. Stolze, D.R. Mole and P.J. Ratcliffe, Regulation of HIF: Prolyl hydroxylases, Novartis Found Symp 272 (2006), 15-25; discussion 25-36.
35. R. Bos, H. Zhong, C.F. Hanrahan, E.C. Mommers, G.L. Semenza, H.M. Pinedo, M.D. Abeloff, J.W. Simons, P.J. van Diest and E. van der Wall, Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis, J Natl Cancer Inst 93 (2001), 309-314.
36. J.P. Dales, S. Garcia, S. Meunier-Carpentier, L. Andrac-Meyer, O. Haddad, M.N. Lavaut, C. Allasia, P. Bonnier and C. Charpin, Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: Retrospective study in a series of 745 patients, Int J Cancer 116 (2005), 734-739.
37. H. Zhong, A.M. De Marzo, E. Laughner, M. Lim, D.A. Hilton, D. Zagzag, P. Buechler, W.B. Issacs, G.L. Semenza and J.W. Simons, Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases, Cancer res 59 (1999), 5830-5835.
38. R. Bos, P. van der Groep, A.E. Greijer, A. Shvarts S. Meijer, H.M. Pinedo, G.L. Semenza, P.J. van Diest and E. van der Wall, Levels of hypoxia-inducible factor-1aplha independently predict prognosis in patients with lymph node negative breast carcinoma, Cancer 97 (2003), 1573-1581.
39. M.M. Vleugel, A.E. Greijer, A. Shvarts, P.van der Groep, M. van Berkel, Y. Aarbodem, H. van Tinteren, A.L. Harriz, P.J. van Diest and E. van der Wall, Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer, J Clin Pathol, 58 (2005), 172-177.
40. R. Bos, P.J. van Diest, J.S. de Jong, P. van der Groep, P. van der Valk and E. van der Wall, Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer, Histopathology 46 (2005), 31-36.
41. R. Bos, J.J. van Der Hoeven, E. van Der Wall, P. van Der Groep, P.J. van Diest, E.F. Comans, U. Joshi, G.L. Semenza, O.S. Hoekstra, A.A. Lammertsma and C.F. Molthoff, Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by position emission tomography, J Clin Oncol 20 (2002), 379-387.
42. D. Vordermark, A. Kaffer, S. Riedl, A. Katzer and M. Flentje, Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells, Int J Radiat Oncol Biol Phys 61 (2005), 1197-1207.
43. K.J. Williams, C.A. Parker and I.J. Stratford, Exogenous and endogenous markers of tumour oxygenation status: Definitive markers of tumour hypoxia? Adv Exp Med Biol 566 (2005), 285-294.
44. C. Potter and A.L. Harris, Hypoxia inducible cabonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target, Cell Cycle 3 (2004), 164-167.
45. M. Bartosova, S. Parkkila, K. Pohlodek, T.J. Karttunen, S. Galbavy, V. Mucha, A.L. Harris, J. Pastorek and S. Pastorekova, Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2, J Pathol 197 (2002), 314-321.
46. S.K. Chia, C.C. Wykoff, P.H. Watson, C. Han, R.D. Leek, J. Pastorek, K.C. Gatter, P. Ratcliffe and A.L. Harris, Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma, J Clin Oncol 19 (2001), 3660-3668.
47. P.H. Watson, S.K. Chia, C.C. Wykoff, C. Han, R. D. Leek, W.S. Sly, K.C. Gatter, P. Ratcliffe and A.L. Harris, Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma, Br J Cancer 88 (2003), 1065-1070.
48. P.N. Span, J. Bussink, P. Manders, L.V. Beex and C.G. Sweep, Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome, Br J Cancer 89 (2003), 271-276.
49. C.C. Wykoff, N. Beasley, P.H. Watson, L. Campo, S.K. Chia, R. English, J. Pastorek, W.S. Sly, P. Ratcliffe and A.L. Harris, Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast, Am J Pathol 158 (2001), 1011-1019.
50. M. Weinmann, V. Jendrossek, D. Guner, B. Goecke and C. Belka, Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways, Faseb J 18 (2004), 1906-1908.
51. D.M. Brizel, G.L. Rosner, L.R. Prosnitz and M.W. Dewhirst, Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymphnode metastases, Int J Radiant Oncol Biol Phys 32 (1995), 1121-1125.
52. S. Walenta, M. Wetterling, M. Lehrke, G. Schwickert, K. Sundfor, E.K. Rofstad and W. Mueller-Klieser, High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers, Cancer Res 60 (2000), 916-921.
53. M. Hockel, K. Schlenger, B. Aral, M. Mitze, U. Schaffer and P. Vaupel, Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Res 56 (1996), 4509-4515.
54. R. Airley, J. Loncaster, S. Davidson, M. Bromley, S. Roberts, A. Patterson, R. Hunter, I. Stratford and C. West, Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix, Clin Cancer Res 7 (2001), 928-934.
55. T.G. Graeber, C. Osmanian, T. Jacks, D.E. Housman, C.J. Koch, S.W. Lowe and A.J. Giaccia, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Nature 379 (1996), 88-91.
56. J. Fujimoto, S.M. Alam, I. Jahan, E. Sato, H. Toyoki, B.L. Hong, H. Sakaguchi and T. Tamaya, Plausible linkage of hypoxia inducible factor-1alpha in uterine cervical cancer, Cancer Sci (2006),
57. G.U. Dachs and G.M. Tozer, Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation, Eur J Cancer 36 (2000), 1649-1660.
58. S.D. Young, R.S. Marshall and R.P. Hill, Hypoxia induces DNA overreplication and enhanced metastasis potential of murine tumor cells, Proc Natl Acad Sci USA 85 (1988), 9533-9537.
59. R.P. Hill, K. De Jaeger, A. Jang and R. Cairns, pH, hypoxia and metastasis, Novartis Found Symp 240 (2001), 154-165; discussion 165-158.
60. S.D. Young and R.P. Hill, Effects of reoxygenation on cells from hypoxic regions of solid tumors: Analysis of transplanted murine tumors for evidence of DNA overreplication, Cancer Res 50 (1990), 5031-5038.
61. E.K. Rofstad, B. Mathiesen, K. Henriksen, K. Kindem and K. Galappathi, The tumor bed effect: Increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products, Cancer Res 65 (2005), 2387-2396.
62. K. De Jaeger, M.C. Kavanagh and R.P. Hill, Relationship of hypoxia to metastatic ability in rodent tumours, Br J Cancer 84 (2001), 1280-1285.
63. N. Chaudary, A. Yuen and R.P. Hill, Expression of metastatic genes in hypoxic cells in cervix cancer xenografts and their lymph node metastases: Effects of acute and chronic hypoxia, Cancer Research, manuscript in preparation.
64. R.A. Cairns and R.P. Hill, Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma, Cancer Res 64 (2004), 2054-2061.
65. R.A. Cairns, T. Kalliomaki and R.P. Hill, Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors, Cancer Res 61 (2001), 8903-8908.
66. R.P. Hill, Tumor progression: Potential role of unstable genomic changes, Cancer Metastasis Rev 9 (1990), 137-147.
67. L. Zhang and R.P. Hill, Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis, Cancer Res 64 (2004), 4180-4189.
68. C.Y. Kimm, M.H. Tsai, C. Osmanian, T.G. Graeber, J.E. Lee, R.G. Giffard, J.A. DiPaolo, D.M. Peehl and A.J. Giaccia, Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions, Cancer Res 57 (1997), 4200-4204.
69. O. Amellem, T. Stokke, J.A. Sandvik, L. Smedshammer and E.O. Pettersen, Hypoxia-induced apoptosis in human cells with normal p53 status and function, without any alteration in the nuclear protein level, Exp Cell Res 232 (1997), 361-370.
70. M.J. van de Vijver, Y.D. He, L.J. van't Veer, H. Dai, A.A. Hart, D.W. Voskuil, G.J. Schreiber, J.L. Peterse, C. Roberts, M.J. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, T. van der Velde, H. Bartelink, S. Rodenhuis, E.T. Rutgers, S.H. Friend and R. Bernards, A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med 347 (2002), 1999-2009.
71. T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, T. Thorsen, H. Quist, J.C. Matese, P.O. Brown, D. Botstein, P. Eystein Lonning and A.L. Borresen-Dale, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci USA 98 (2001), 10869-10874.
72. C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lonning, A.L. Borresen-Dale, P.O. Brown and D. Botstein, Molecular portraits of human breast tumours, Nature 406 (2000), 747-752.
73. B. Weigelt, Z. Hu, X. He, C. Livasy, L.A. Carey, M.G. Ewend, A.M. Glas, C.M. Perou and L.J. Van't Veer, Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer, Cancer Res 65 (2005), 9155-9158.
74. J.T. Chi, Z. Wang, D.S. Nuyten, E.H. Rodriguez, M.E. Schaner, A. Salim, Y. Wang, G.B. Kristensen, A. Helland, A.L. Borresen-Dale, A. Giaccia, M.T. Longaker, T. Hastie, G.P. Yang, M.J. Vijver and P.O. Brown, Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers, PLoS Med 3 (2006), e47.
75. S. Ramaswamy, K.N. Ross, E.S. Lander and T.R. Golub, A molecular signature of metastasis in primary solid tumors, Nat Genet 33 (2003), 49-54.
76. R.P. Hill, Book review, Int J Radiat Biol 82 (2006), 523.
77. A. Muller, B. Homey, H. Soto, N. Ge, D. Catron, M.E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S.N. Wagner, J.L. Barrera, A. Mohas, E. Verastegui and A. Zlotnik, Involvement of chemokine receptors in breast cancer metastasis, Nature 410 (2001), 50-56.
78. H. Bando, M. Toi, K. Kitada and M. Koike, Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231, Biomed Pharmacother 57 (2003), 333-340.
79. L.A. Shevde and D.R. Welch, Metastasis suppressor pathways - an evolving paradigm, Cancer Lett 198 (2003), 1-20.
80. H. Kim and W.J. Muller, The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis, Exp Cell Res 253 (1999), 78-87.
81. D.A. Kirschmann, E.A. Seftor, D.R. Nieva, E.A. Mariano and M.J. Hendrix, Differentially expressed genes associated with the metastatic phenotype in breast cancer, Breast Cancer Res Treat 55 (1999), 127-136.
82. N. Lapteva, A.G. Yang, D.E. Sanders, R.W. Strube and S.Y. Chen, CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo, Cancer Gene Ther 12 (2005), 84-89.
83. M. Kato, J. Kitayama, S. Kazama and H. Nagawa, Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma, Breast Cancer Res 5 (2003), R144-R150.
84. M. Darash-Yahana, E. Pikarsky, R. Abramovitch, E. Zeira, B. Pal, R. Karplus, K. Beider, S. Avniel, S. Kasem, E. Galun and A. Peled, Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis, Faseb J 18 (2004), 1240-1242.
85. B.C. Schmid, M. Rudas, G.A. Rezniczek, S. Leodolter and R. Zeillinger, CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia, Breast Cancer Res Threat 84 (2004), 247-250.
86. H. Shim, S.K. Lau, S. Devi, Y. Yoon, H. T. Cho and Z. Liang, Lower expression of CXCR4 in lymphnode metastases than in primary breast cancers: Potential regulation by ligand-dependent degradation and HIF-1alpha, Biochem Biophys Res Commun 346 (2006), 252-258.
87. Z. Liang, Y. Yoon, J. Votaw, M.M. Goodman, L. Williams and H. Shim, Silencing of CXCR4 blocks breast cancer metastasis, Cancer Res 65 (2005), 967-971.
88. Y. Chen, C. Miller, R. Mosher, X. Zhao, J. Deeds, M. Morrissey, B. Bryant, D. Yang, R. Meyer, F. Cronin, B.S. Gostout, K. Smith-McCune and R. Schlegel, Identification of cervival cancer markers by cDNA and tissue microarrays, Cancer Res 63 (2003), 1927-1935.
89. J.D. Holland, M. Kochetkova, C. Akekawatchai, M. Dottore, A. Lopez and S.R. McColl, Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells, Cancer Res 66 (2006), 4117-4124.
90. K.A. Furger, R.K. Menon, A.B. Tuck, V.H. Bramwell and A.F. Chambers, The functional and clinical roles of osteopontin in cancer and metastasis, Curr Mol Med 1 (2001), 621-632.
91. P.S. Rudland, A. Platt-Higgins, M. El-Tanani, S. De Silva Rudland, R. Baraclough, J.H. Winstanley, R. Howitt and C.R. West, Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer, Cancer Res 62 (2002), 3417-3427.
92. A.B. Tuck, F.P. O'Malley, H. Singhal, K.S. Tonkin, J.F. Harris, D. Bautista and A.F. Chambers, Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas, Arch Pathol Lab Med 121 (1997), 578-584.
93. C. Gao, Z. Mi, H. Guo, J. Wei, P.Y. Wai and P.C. Kuo, A transcriptional repressor of osteopontin expression in the 4T1 murine breast cancer cell line, Biochem Biophys Res Commun 321 (2004), 1010-1016.
94. L.A. Shevde, R.S. Samant, J.C. Paik, B.J. Metge, A.F. Chambers, G. Casey, A.R. Frost and D.R. Welch, Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435, Clin Exp Metastasis 23 (2006), 123-133.
95. M.K. El-Tanani, F.C. Campbell, P. Crowe, P. Erwin, D.P. Harkin, P. Pharoah, B. Ponder and P.S. Rudland, BRCA1 suppresses osteopontin-mediated breast cancer, J Biol Chem 281 (2006), 26587-26601.
96. J.T. Erler, K.L. Bennewith, M. Nicolau, N. Dornhofer, C. Kong, Q.T. Le, J.T. Chi, S.S. Jeffrey and A.J. Giaccia, Lysyl oxidase is essential for hypoxia-induced metastasis, Nature 440 (2006), 1222-1226.
97. S.L. Payne, B. Fogelgren, A.R. Hess, E.A. Seftor, E.L. Wiley, S. F. Fong, K. Csiszar, M.J. Hendrix and D.A. Krischmann, Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism, Cancer Res 65 (2005), 11429-11436.
98. D.A. Kirschmann, E.A. Seftor, S.F. Fong D.R. Nieva, C.M. Sullivan, E.M. Edwards, P. Sommer, K. Csiszar and M.J. Hendrix, A molecular role for lysyl oxidase in breast cancer invasion, Cancer Res 62 (2002), 4478-4483.
99. B. Han, M. Nakamura, I. Mori, Y. Nakamura and K. Kakudo, Urokinase-type plaminogen activator system and breast cancer (Review), Oncol Rep 14 (2005), 105-112.
100. R. Subramanian, C.S. Gondi, S. S. Lakka, A Jutla and J.S. Rao, siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells, Int J Oncol 28 (2006), 831-839.
101. M.C. Smith, K.E. Luker, J.R. Garbow, J. L. Prior, E, Jackson, D. Piwnica-Worms and G.D. Luker, CXCR4 regulates growth of both primary and metastatic breast cancer, Cancer Res 64 (2004), 8604-8612.
102. P. Staller, J. Sulitkova, J. Lisztwan, H. Moch, E.J. Oakeley and W. Krek, Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL, Nature 425 (2003), 307-311.
103. Y.L. Liu, J.M. Yu, X.R. Song, X.W. Wang, L.G. Xing and B.B. Gao, Regulation of the Chemokine Receptor CXCR4 and Metastasis by Hypoxia-inducible Factor in Non Small Cell Lung Cancer Cell Lines, Cancer Biol Ther 5 (2006).
104. A. Maity and D. Solomon, Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by by hypoxia, Exp Cell Res 255 (2000), 250-257.
105. S.Y. Yoon, Y.J. Lee, J.H. Seo, H. J. Sung, K. H. Park, I.K. Choi, S.J. Kim, S.C. Oh, C.W. Choi, B.S. Kim, S.W. Shin, Y.H. Kim and J.S. Kim, uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line, Cell Res 16 (2006), 75-81.
106. S. Memarzadeh, K.R. Kozak, L. Chang, S. Natarajan, P. Shintaku, S.T. Reddy and R. Farias-Eisner, Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer, Proc Natl Acad Sci USA 99 (2002), 10647-10652.
107. S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano and P.M. Comoglio, Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene, Cancer Cell 3 (2003), 347-361.
108. C. Baykal, A. Ayhan, A. Al, K. Yuce and A. Ayhan, Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix car carcinomas, Gynecol Oncol 88 (2003), 123-129.
109. P.C. Ma, G. Maulik, J. Christensen and R. Salgia, c-Met: Structure, functions and potential for therapeutic inhibition, Cancer Metastasis Rev 22 (2003), 309-325.
110. A. Ayhan, D. Ertunc, E.C. Tok and A. Ayhan, Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance, Int J Gynecol Cancer 15 (2005), 618-623.
111. T. Funasaka, T. Yanagawa, V. Hogan and A. Raz, Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia, Faseb J 19 (2005), 1422-1430.
112. S. Tsutsumi, T. Yanagawa, T. Shimura, H. Kuwano and A. Raz, Autocrine motility factor signaling enhances pancreatic cancer metastasis, Clin Cancer Res 10 (2004), 7775-7784.
113. D. Nie, S. Krishnamoorthy, R. Jin, K. Tang, Y. Chen, Y. Qiao, A. Zacharek, Y. Guo, J. Milanini, G. Pages and K. V. Honn, Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells, J Biol Chem 281 (2006), 18601-18609.
114. W.Y. Kim, M. Safran, M.R. Buckley, B.L. Ebert, J. Glickman, M. Bosenberg, M. Regan and W.G. Kaelin, Jr., Failure to prolyl hydroxylate hypoxia-inducible factor alpha pheno-copies VHL inactivation in vivo, Embo J (2006).
115. S.F. Schoppmann, A. Fenzl, M. Schindl, T. Bachleitner-Hofmann, K. Nagy, M. Gnant, R. Horvat, R. Jakesz and P. Birner, Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer, Breast Cancer Res Treat 99 (2006), 135-141.
116. K. Okada, M. Osaki, K. Araki, K. Ishiguro, H. Ito and S. Ohgi, Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas, Anticancer Res 25 (2005), 3003-3009.
117. J. Fujimoto, H. Toyoki, E. Sato, H. Sakaguchi and T. Tamaya, Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers, Br J Cancer 91 (2004), 466-469.
118. T. Tsurusaki, S. Kanda, H. Sakai, H. Kanetake, Y. Saito, K. Alitalo and T. Koji, Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis, Br J Cancer 80 (1999), 309-313.
119. P.L. Marjon, E.V. Bobrovnikova-Marjon and S.F. Abcouwer, Expression of the pro-angiogenic factor vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endo-plasmic reticulum stress, Mol Cancer 3 (2004), 4.
120. E.V. Bobrovnikova-Marjon, P.L. Marjon, O. Barbash, D.L. Vander Jagt and S.F. Abcouwer, Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: Role of nuclear factor-kappaB and activating protein-1, Cancer Res 64 (2004), 4858-4869.
121. S.K. Kassim, E. M. El-Salahy, S.T. Fayed, S.A. Helal, T. Helal, D. Azzam Eel and A. Khalifa, Vascular endothelial growth factor interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients, Clin Biochem 37 (2004), 363-369.
122. S. Lukacova, A.A. Khalil, J. Overgaard, J. Alsner and M.R. Horsman, Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum, Int J Radiat Biol 81 (2005), 937-944.
123. H.M. Said, A. Katzer, M. Flentje and D. Vordermark, Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells, Radiother Oncol 76 (2005), 200-205.
124. Q.T. Le, P.D. Sutphin, S. Raychaudhuri, S.C. Yu, D.J. Terris, H.S. Lin, B. Lum, H.A. Pinto, A.C. Koong and A.J. Giaccia, Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas, Clin Cancer Res 9 (2003), 59-67.